Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL +2.89%39 3-Year EPS without NRI Growth Rate is 30.10% as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 39/100 and a GF Value™ of A$2.92 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 658 Medical Devices & Instruments companies, OncoSil Medical ranks better than 77.96% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 30.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 9.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 5.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of OncoSil Medical was 72.70% per year. The lowest was -203.80% per year. And the median was -4.00% per year.
OncoSil Medical (ASX:OSL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
OncoSil Medical 3-Year EPS without NRI Growth Rate Related Terms
ASX:OSL vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, OncoSil Medical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's 3-Year EPS without NRI Growth Rate falls into.
OncoSil Medical 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 30.10% mean?
OncoSil Medical (ASX:OSL) has a 3-Year EPS without NRI Growth Rate of 30.10% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #145 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 22%.
Is OncoSil Medical's 3-Year EPS without NRI Growth Rate too high?
OncoSil Medical's current 3-Year EPS without NRI Growth Rate is 30.10%. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. OncoSil Medical's value of 30.10% is 273.9% above this industry median. Based on the distribution chart, OncoSil Medical ranks #145 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OncoSil Medical has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #145 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places OncoSil Medical in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. OncoSil Medical's value of 30.10% is 273.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current 3-Year EPS without NRI Growth Rate of 30.10% is 273.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current 3-Year EPS without NRI Growth Rate is 30.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.25 — trading 57.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 30.10% and 273.9% above the Medical Devices & Instruments industry median of 8.05. OncoSil Medical's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current 3-Year EPS without NRI Growth Rate is 30.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.25 is trading 57.4% below its estimated GF Value™ of A$2.92.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
3-Year EPS without NRI Growth Rate: 30.10%
GF Value™: A$2.92 vs. price of A$1.25 (57.4% below fair value)
Industry Position: 273.9% above the Medical Devices & Instruments median (#145 of 658)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
39GF Score
Get the complete analysis for ASX:OSL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
